AboutContact us
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
The 50 most promising Israeli startups - 2026
2
Five bidders advance in Nice’s $2.5 billion Actimize sale process
3
From Iron Dome to Arrow missiles, unpaid bills accumulate in Israel’s defense sector
4
Why Alphabet’s CapitalG is still betting on Israel
5
SAP taps Israeli executive to lead global AI push
More news

Advent

7 stories about Advent
רוני על דור ו משרדי סאפיינס בישראל

Sapiens layoffs: “Anyone not asked to prepare layoff lists knew they were on it”

30.12.25|Sophie Shulman
Employees describe shock, demotions, and a rapid overhaul following Advent’s $2.5 billion takeover.
רוני על דור ו משרדי סאפיינס בישראל

After a $2.5 billion exit, Sapiens cuts 700 jobs and replaces its entire management

28.12.25|Sophie Shulman
EXCLUSIVE: Advent’s takeover swiftly reshapes the Israeli software company’s leadership and workforce. 
דיוויד מוסאפר שותף מנהל ב אדוונט ו גיא ברנשטיין מנכ"ל פורמולה

Advent bets on cloud transition with $2.5 billion Sapiens acquisition

14.08.25|Almog Azar
Insurtech’s U.S. market ambitions hinge on private equity’s deep network.
רוני על‐דור מנכ"ל ונשיא סאפיינס ו גיא ברנשטיין מנכ"ל פורמולה

Advent to acquire Sapiens for $2.5 billion, ending its public market run

13.08.25|Almog Azar, CTech
Insurance software maker to go private at 64% premium as private equity bets on SaaS and AI transformation.
אסף רזניק אליק איזנברג BigPanda

BigPanda enters unicorn club with $190 million funding at $1.2 billion valuation

12.01.22|Meir Orbach
The IT management company raised the sum in two rounds over a month-and-a-half in late 2021
מנכ"ל פורסקאוט מייקל דסיזאר

Advent Delays $1.9 Billion ForeScout Acquisition

19.05.20|Hagar Ravet
The companies are in ongoing discussions concerning the timing and terms of completion, but, according to ForeScout, there can be no assurance that they could reach an agreement
מפעל טבע הר חוצבים ירושלים

Cerberus, Advent Eye Teva's European Assets, Report Says

15.08.17|Calcalist
The private equity firms are taking an interest in Teva's European oncology and pain treatment assets, estimated at $700 million to 1$ billion, according to a Bloomberg report